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Abstract 
Sol-Gel chemistry has been successfully used to prepare un-doped and Sr-doped calcium 
phosphate ceramics exhibiting a porous structure. The samples composition is very close to 
the nominal one. All samples present phase mixtures mainly Hydroxyapatite (HAp) and Tri 
Calcium Phosphate (β-TCP). Doping with Sr2+ ions has a clear effect on the proportions of 
the different phases, increasing the amount of β-TCP. An amorphous phase is also observed 
incorporating some 40 % of the total amount of strontium. Strontium ions also substitute for 
calcium both in HAp and β-TCP in specific sites that have been determined from Rietveld 
refinement on synchrotron powder diffraction data. The soluble amorphous and TCP phases 
are responsible for a beneficial partial release of strontium ions in solution during interactions 
between the material and biological fluids. Preliminary in vitro study demonstrates anti-
inflammatory effect of strontium for human monocytes cultured in contact with calcium 
phosphates. 
 
 
1. Introduction 
Due to the global aging of the population, the need for bone substitutes is increasing very 
quickly. There is also a strong demand for bioceramics with specific properties such as anti-
inflammatory, bactericidal or anti osteoporotic. Bone mineral mass is dominated by nano-
crystalline non-stoichiometric hydroxyapatite (Hap, Ca5(PO4)3OH) and whitlockite (β-TCP, 
β-Ca3(PO4)2) can be found at many different sites in the human body [1-3]. For these reasons, 
apatite and whitlockite have been widely used as biocompatible materials for bone 
replacement and for bone protheses coating [4]. An interesting alternative is the use of so 
called Biphasic Calcium Phosphate (BCP) which is mixture of HAp and β-TCP. Because of 
the difference in the solubility of the two phases, the solution behaviour of BCP can be easily 
tuned. Another interesting possibility is to perform ionic substitution in calcium phosphates to 
improve their properties and to modulate their bioactivity.  
Similarly to the case of Ca, an estimated 99% of the total amount of Sr in the body is confined 
in bone [1]. The total amount of Sr in human skeleton is small but not insignificant; the Sr/Ca 
ratio is in the range 0.1-0.3 weight ‰ [5]. Sr is readily taken up in bone [6]. Various studies 
investigating the therapeutical and detrimental effects of Sr have been carried out on animals 
and humans [1, 7-12]. In vitro and in vivo studies have indicated that oral strontium intake not 
only increases bone formation, the number of bone-forming sites and the bone mineral 
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density, but also reduces bone resorption [1,10-12]. Sr is used for treatment of osteoporosis 
[13,14], and was found to induce osteoblast activity when introduced in biocompatible bone 
cements [15-19]. A better osteointegration has been observed when Sr is present at low 
concentration level in biomaterials. The role of strontium in human pathology has attracted 
less attention than the other two important alkaline earths calcium and magnesium. However 
there has been an increasing awareness of the potential biological role of strontium and its 
incorporation in calcium phosphate cements has been largely studied in the last decade 
[15,16,20-30]. The purpose of this study was to examine the incorporation of Sr2+ ions in 
hydroxyapatite sample at the atomic level: identification and quantification of the crystallised 
phases, identification of the Sr-occupied crystallographic sites, identification of an amorphous 
phase and determination of the chemical composition of the different phases. 
 
2. Experimental 
2.1 Sol-Gel elaboration of Sr-substituted hydroxyapatite 
 
The sol-gel route previously proposed by the authors [31, 32] has been used. Briefly, to 
produce 2 g of pure HAp powder, 4.7 g of Ca(NO3)2·4H2O (Aldrich), 0.84 g of P2O5 
(Avocado Research chemicals) were dissolved in ethanol under stirring and refluxed at 85°C 
during 24 h. Then, this solution was kept at 55°C during 24 h, to obtain a white consistent gel 
and further heated at 80°C during 10 h to obtain a white powder. Finally, the powder was 
heated at 1100°C during 15 h. To prepare Sr-substituted hydroxyapatite, the required amount 
of Sr(NO3)2 (Aldrich) was added to the solution.  
Two samples have been studied: pure hydroxyapatite sample (named ‘HAp’ in this paper) of 
nominal composition Ca5(PO4)3·OH and 5% Sr-doped hydroxyapatite sample: named 
‘Sr:HAp’ in the following. The doped sample corresponds to an hydroxyapatite where 5 
atomic % of calcium have been replaced by strontium atoms thus achieving the nominal 
composition Ca4.75Sr0.25(PO4)3·OH. 
The chemical composition of the hydroxyapatite powders were determined by ICP-AES 
(Inductively Coupled Plasma-Atomic Emission Spectrometry). The nominal and experimental 
compositions of the two HAp samples are listed in Table 1. As usually observed for sol-gel 
derived ceramics [33], the nominal compositions have been readily achieved. 
 
2.2 Characterization of HAp samples 
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Scanning Electron Microscopy Analysis 
 The hydroxyapatite powders were deposited on carbon disks and sputter-coated with 
20 nm of gold. Then, the samples were examined using a JEOL JSM-5910 LV scanning 
electron microscope at an accelerating voltage of 15 kV.  All the images were recorded using 
the secondary electrons detector. A representative SEM image is shown in Figure 1 
demonstrating the porosity of sol-gel derived HAp samples. 
 
[Figure 1 around here] 
 
Specific Surface Area(SSA) measurements 
SSAs were calculated with the BET model from the adsorption isotherm measured by 
nitrogen sorption analyses at 77 K using an Autosorb MP1 Quantachrome equipment. SSAs 
are found to be equivalent for both samples around 0.5 m2.g-1. These values were considered 
for in vitro release studies keeping a constant surface/volume ratio. 
 
In vitro Sr2+ release studies 
The interactions between the ceramics and a biological medium have been carried out at 37°C 
for 1 to 6 days by immersing about 10 mg of powder in a standard Dulbecco’s Modified 
Eagle Medium (DMEM), which composition is almost identical to the one of human plasma. 
The specific surface area to DMEM volume ratio was fixed at 500 cm-1. These in vitro assays 
were conducted under static conditions: biological fluids were not renewed and therefore 
contained only limited amount of P and Ca. Namely, this is a good approach for further 
development and to compare different doping elements and compositions. ICP-AES was used 
to analyze the biological fluid before and after bioceramics interactions. 
 
2.3 X-rays powder diffraction 
 
Synchrotron measurement 
Synchrotron powder diffraction data of both samples were obtained at ESRF (Grenoble, 
France) on the SNBL. Finelly grinded powders were introduced into a 0.3 mm diameter glass 
capillary. Data collections were performed at 295 K with a MAR345 Image Plate detector by 
using a monochromatic wavelength of λ = 0.710130 Å. The calculated absorption coefficient 
was mµR = 0.68 (m = powder packing factor and µ = linear absorption coefficient, R = radius 
of the capillary, 0.15 mm). Two sample-to-detector distances were used (150 and 350 mm) in 
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order to combine the benefits of a high resolution and an extended 2θ range. The detector and 
the wavelength were calibrated with NIST LaB6. The highest resolution of the MAR345 
detector was used: 3450 x 3450 pixels with a pixel size of 100 µm. The exposure time was 60 
seconds with a rotation of the capillary by 60°. The two-dimentionnal data were intergreted 
with Fit2D program [34] which produced correct intensity in relative scale. This 2D detector 
was used in order to perfectly define the background line, to observe very weak diffraction 
peaks, and to improve an accuracy of the integrated intensities by achieving a better powder 
average. Uncertainties of the integrated intensities were calculated at each 2θ-point applying 
Poisson statistics to the intensity data, considering the geometry of the detector. The 
Instrument Resolutions Functions were determined from the LaB6 data. 
 
Rietveld refinements 
Joint Rietveld refinements based on the simultaneous use of the data measured at 150 mm 
(large two theta interval) and 350 mm (high resolution) sample to detector distances were 
performed for both samples with the program Fullprof.2k Multi-Pattern [35]. Three phases 
have been refined for the HAp sample: hydroxyapatite, whitlockite and lime. For the Sr:HAp 
sample, portlandite has been introduced as the fourth phase. The absence of calcite in both 
samples has been verified. The structural parameters of hydroxyapatite, Ca5(PO4)3·OH, were 
taken from [36]: space group P63/m, Z = 2, a = 9.4218 Å and c = 6.8813 Å, 7 independent 
atomic positions: two Ca, one P and four O positions. The O4 oxygen position (i.e. the 
hydroxyl anion) is half occupied, this corresponds to a statistically disordered 4e position 
around the 2a (0,0,¼) site. The structural parameters of whitlockite, β-Ca3(PO4)2, were taken 
from [37]: space group R3c, Z = 21, a = 10.4352 Å and c = 37.4029 Å, 18 independent atomic 
positions: five Ca, three P positions  and ten O positions. The structural parameters of lime, 
CaO, were taken from [38]: space group mFm3 , Z = 4, a = 4.8071 Å. And the structural 
parameters of portlandite, Ca(OH)2, were taken from [39]: space group 13mP , Z = 1, a = 
3.589 Å and c = 4.911 Å. In a first step all the structural parameters were fixed according to 
the literature values. Then during the successive refinement cycles they were all refined (first 
lattice parameters and peak profiles, and next atomic parameters: positional, isotropic 
temperature and occupancy factors). In the final run, 96 and 115 parameters were refined for 
the HAp sample (2 zero shifts, 6 scale factors, 20 profil parameters and 68 structural 
parameters) and for the Sr:HAp sample (2 zero shifts, 8 scale factors, 28 profil parameters and 
77 structural parameters) respectively. The determination of the Instrumental Resolution 
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Function (extracted from the powder patterns recorded on NIST LaB6 powder) improved the 
peak profile modelling while decreasing the number of profile parameters. It allowed also the 
extraction of the sample intrinsic microstructural parameters: average apparent crystallite size 
and average maximum strain. The diffraction profiles (both instrumental and sample intrinsic) 
were modelled by using a Thomson-Cox-Hastings pseudo-Voigt function [35]. Refinement 
with the anisotropic line broadening procedure [35] did not improve significantly the fit. 
Correction applied by taking into account microabsorption effect, as indicated by [40], did not 
affect the quantitative Rietveld analysis result (due to a nearly equivalent linear absorption 
coefficient for all the phases). The use of the monoclinic ordered structural description for the 
hydroxyapatite phase [41] did not allow increasing the accuracy of the refinement. The last 
refinement cycles were performed by introducing hydrogen atom from hydroxyl anion. The 
H4 position was located the site 4e (in accordance with [37]), a soft constraint of 0.92 ± 0.05 
Å was applied to the distance O4-H4, and the isotropic temperature factors of H4 was 
constrained to be 1.2 times Biso of the corresponding oxygen atom O4 as it is usual for 
hydroxyl groups [42]. The final refined dO4-H4 distances were 0.89(2) Å and 0.92(2) Å for 
respectively the pure and the Sr-doped hydroxyapatite phase. Previously unconstrained 
distance converged to 0.67(7) Å in the case of the pure hydroxyapatite phase, and did not 
converge in the case of the Sr-doped hydroxyapatite phase. The refined structural parameters 
for hydroxyapatite and whitlockite phases are respectively summarized in Table 2 and Table 
3. Rietveld plots are shown in Figures 2 and 3 for HAp and Sr:HAp samples, respectively. 
 
[Tables 2 and 3 around here] 
 
[Figures 2 and 3 around here] 
 
2.4 Preliminary biological study of inflammation reactions 
Cell culture 
Elutriated monocytes were used to evaluate Tumor Necrosis Factor (TNF-α) production. 
Monocytes from five healthy consenting donors were collected by leukapheresis and purified 
by counterflow elutriation. Purity, after CD14 staining, was at least 95%, the rest being 
neutrophils. Cells were maintained in RPMI-1640 medium (Life Technologies, France) 
supplemented with 10% fetal calf serum (Life Technologies, France), 2 mM glutamine, 
penicillin (5000 U.mL-1, Life Technologies) and streptomycin (25 µg.mL-1, Life 
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Technologies) at 37°C in a saturated 5% CO2 - 95% air atmosphere. All reagents were 
certified endotoxin-free. The cells were cultured in petri dishes (Life Technologies). The 
density was 2.105 cells.mL-1 in a 5 mL total volume. Cells of each donor were exposed during 
6h (time chosen to have an interaction between cells and particles) to the different particles 
described above. The negative control consisted of monocytes in culture medium alone (data 
not shown) and the positive control was monocytes plus LipoPolySaccharide (LPS). LPS 
(Sigma-Aldrich) were chosen because of their inflammatory actions on the target cells.  
The viability of cells was evaluated by trypan blue exclusion test. The viability was >95% in 
all of the experiments (before and after exposure to particles). 
Quantification of TNF-α by ELISA 
After 6h, TNF-α determinations in cell culture supernatants were performed using 
commercially available ELISA kits (Quantikine, R&D Systems, Inc., Minneapolis, MN) 
according to the manufacturer’s instructions. The sensitivity of each kit was 7.8 pg.mL-1. 
Results are presented in relative concentration. Results were presented as median ± 
interquartile space (IQS) of relative variation between positive control and stimulated cells.  
A Mann & Whitney non parametric test was performed to compare the different conditions. 
 
3. Results and discussion 
3.1 Quantitative phases analysis 
Quantitative phases analysis has been performed on the basis of the joint Rietveld 
refinements. Three phases have been observed and quantified in case of HAp sample (apatite, 
whitlockite and lime). Portlandite has been introduced as the fourth phase in Sr:HAp sample. 
Results of the quantitative phase analysis are summarized in Table 4. 
 
[Table 4 around here] 
 
Synthesis conditions correspond to hydroxyapatite single phase samples; i.e. a (Ca+Sr)/PO4 
ratio of 1.67. However both syntheses yielded multiphase samples. The HAp sample 
contained 93 wt % of apatite but only 65 % for Sr-HAp. The presence of whitlockite, with a 
lower Ca/PO4 ratio of 1.50 was compensated by the presence of CaO. Nevertheless a deficit in 
alkaline earth atoms was observed: it is in the range of the standard deviation in the case of 
HAp sample, and more pronounced in the case of Sr:HAp sample (i.e. respectively 1.66(2) 
and 1.63(3) refined ratios). This deficit in the case of Sr:HAp sample has to be explained by 
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the presence of an alkaline-earth rich amorphous phase, not accessible by X-ray diffraction. 
This amorphous phase can be expressed as an amorphous (Ca,Sr)O equivalent. According to 
the apparent Sr deficit in the crystallised phases (indicated by the refined compositions of 
Ca4.88(1)Sr0.12(1)(PO4)3(OH) and Ca2.87(6)Sr0.13(6)(PO4)2 leading to a Sr amount of only 2.86(4) 
%) the amorphous (Ca,Sr)O should mainly be composed of strontium oxide. Calculation has 
been performed, in the case of Sr:HAp sample, to estimate the amount of amorphous phase by 
simultaneous comparison of the nominal and refined (Ca+Sr)/PO4 ratios and the nominal and 
refined Sr amounts (see Table 4). An estimation of 2.2 wt % of amorphous (Ca,Sr)O, which in 
composed at around 90 wt % by strontium oxide, was obtained. These results indicates that a 
large amount of about 40 % of the Sr introduced during the synthesis is present in the 
amorphous phase, about 32 % is inserted in the apatite phase (of composition 
Ca4.88(1)Sr0.12(1)(PO4)3·OH, relatively far from the theoretical Ca4.75Sr0.25(PO4)3·OH 
composition corresponding to the synthesis of a single phase Sr:HAp sample) and about 28 % 
is inserted in the whitlockite phase (with the Ca2.87(6)Sr0.13(6)(PO4)2 composition). Rietveld 
refinement for the HAp sample indicated that a very small amount of CaO (i.e. 0.2 wt %) led 
to the formation of a noticeable amount of whitlockite (i.e. 7.0 wt %) due to the close Ca/PO4 
ratio between hydroxyapatite (1.67) and whitlockite (1.50) phases. Introduction of strontium 
during the synthesis increased the formation of the alkaline earth oxide with a poorly 
crystalline feature (from 0.2 wt % in HAp sample to about 3 wt % in Sr:HAp sample by 
considering lime, portlandite and the amorphous equivalent) which is likely located at the 
surface of the crystallised grains of hydroxyapatite and withlockite in the form of thin 
amorphous surface layer). The appearance of whitlockite in the Sr containing apatite samples 
has been previously reported [22, 24, 43]. Nevertheless the presence of a small amount (less 
than 1 wt % evaluated from high quality X-ray powder patterns) of CaO, as well as Ca(OH)2 
and the amorphous equivalent, simultaneously with the whitlockite phase indicated that the 
whitlockite formation is not attributed to the non-stoichiometry of the apatite structure. At 
high temperature, the Sr-doped whitlockite phase is more stable than the Sr-doped 
hydroxyapatite phase and its formation is compensated by the combined extraction of alkaline 
earth oxide in order to keep the ratio (Ca+Sr)/PO4 = 1.67. This observation correlates with the 
fact that single phase poorly crystalline Sr-HAp samples are obtained by a moderate heat 
treatment [20,28]. Such a hydroxyapatite inhibiting formation, favouring whitlockite 
formation has already been described in the case of smaller Mg2+ ions insertion [44]. 
 
3.2 Sr-hydroxyapatite solid solution study 
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This study investigated to Ca-rich side of the Sr-apatite solid solution, i.e. Ca5-xSrx(PO4)3·OH 
with x = 0 and 0.12. The solid solution extends from x = 0 (i.e. undoped hydroxyapatite) to x 
= 5 (i.e. belovite Sr5(PO4)3(OH) [46]). Figure 4 reports the lattice parameters and unit cell 
volume variations in the solid solution according to the present study and from the literature 
for x = 0 [34], 0.09 [46], 0.51 [47], 1.158 [47], 3.192 [47] and 5 [45]. The compound with x = 
0.09 [46] has to be carefully considered here because of its non stoechiometric hydroxyl 
amount as indicated by its composition Ca4.71Sr0.09H0.2(PO4)3(OH)0.80. Lattice parameters 
indicated in [28] for x = 0, 0.003, 0.015 and 0.15 (i.e. a = 9.3689, 9.3825, 9.3997 and 9.4252 
Å respectively, and c = 6.8798, 6.8929, 6.9060 and 6.9591 Å respectively) are not considered 
here as they differ significantly from the other values. 
 
[Figure 4 around here] 
 
The variation of the unit cell as a function of the x value follows a linear Vegard’s law. A 
careful examination of these dependences at the Ca-rich side revealed a slight deviation from 
the linear Vegard’s law for both a and c lattice parameters, and consequently for the unit cell 
volume (see insets in Figure 4). This observation should be correlated with the preferential 
insertion of strontium atoms in the 6h site; i.e. the site Ca2 connected to the disordered O4 
position of the hydroxyl anion (see Figure 5). 
 
[Figure 5 around here] 
 
The statistical occupancy disorder of this O4 position corresponds to a shift from the special 
2a position (0,0,¼). This O4 site is the only oxygen position that do not belong to a rigid 
phosphate [PO4]3- tetrahedra. An increase of the O4 shift from the special 2a site can locally 
accommodate the replacement of calcium atoms by bigger strontium atoms. The displacement 
of O4 position from (0,0,0.2030) to (0,0,0.191) allowed to increase the Ca2-O4 distances 
(represented with broken bonds in Figure 5b) from 2.38 Å in the pure hydroxyapatite phase to 
2.40 Å in the Sr-doped hydroxyapatite phase. Rietveld refinement results provide an evidence 
for strontium being located only in the Ca2 site in our low Sr-substituted hydroxyapatite (x = 
0.12). In the same way, Bigi et al. found a preferential substitution of Sr in this Ca2 position 
for x = 0.51, 1.158 and 3.192 [47] (i.e. the occupancy factor for Sr2 position in the 6h site was 
systematically higher than the occupancy factor of Sr1 position in the 4f site). The case with x 
= 0.09 disagrees with this observation, but as already mentioned this compound behaves 
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differently due to its low hydroxyl content [46]. The displacement of the hydroxyl groups 
along the z axis, at low substitution level, accommodates the insertion of Sr atoms in the 
hydroxyapatite structure with a moderate influence on the lattice parameters (i.e. explaining 
the deviation from the linear Vegard’s law at the Ca-rich side of the solid solution). 
 
3.3 Sr-doped whitlockite study 
This study investigated the insertion of small amount of Sr in the whitlockite structure. Table 
3 indicates that Sr is preferentially inserted in the site Ca4. More generally Sr was inserted in 
the low density column described and named by Yashima et al. the A column [37] (see Figure 
2 in [37]). 75 % of inserted Sr atoms are located in this A column (composed of the sites Ca4 
and Ca5), compared to only 25 % of inserted Sr atoms in the dense B column (made of the 
Ca1, Ca2 and Ca3 sites). Figure 6 represents the five independent Ca sites in Sr-free 
whitlockite. The Ca4 site presents an unusually low coordination number (CN = 3) with a 
planar polyhedron in pure whitlockite [37]. If we take into account the three following 
neighbouring oxygen atoms, a coordination number of 6 can be assumed, with three shorter 
dCa4-O1 = 2.53 Å and three larger distances dCa4-O9 = 3.12 Å (the latter are represented by 
broken lines in Figure 6d). Although such coordination polyhedron is more appropriate, a 
deficiency in the calculated bond valence [48] remains for Ca4: the bond valence sum (BVS) 
equals 0.68 or 0.79 by taking into account 3 or 6 neighbouring oxygens respectively. In our 
sample, the half-occupied Ca4 site is 25 % - 25 % occupied by Ca and Sr atoms. This large 
insertion of strontium in the Ca4 site modifies its coordination polyhedron. In the Sr-doped 
whitlockite structure, the Ca4 site has six neighbouring oxygen atoms with quite equivalent 
(Ca, Sr)-O bond distances: three distances dCa4-O1 = 2.63 Å and three distances dCa4-O9 = 2.79 
Å. These six bonds give the calculated BVS of 1.03 (by considering Ca4 occupied by 25 % 
Ca and 25 % Sr) which is still too low for a divalent cation. The insertion of Sr in the Ca4 site 
has clearly a stabilising effect on the whitlockite structure. Not only the geometrical shape of 
the Ca4 polyhedron is considerably improved, but also those for the other cation sites. Figure 
6 represents the environments of all the cationic sites as refined in the Sr-doped whitlockite. 
Ca1, Ca2 and Ca3 compose the dense B column [37] and have CN = 8 with a more or less 
distorted monocapped pentagonal bipyramidal coordination polyhedra. The stabilising effect 
of Sr for the whitlockite structure explains the fact that hydroxyapatite formation was 
inhibited when strontium was introduced during the synthesis process. The stabilizing role of 
Mg in whitlockite has also been reported [49]. Like strontium, Mg2+ cation is located in the A 
column with a large preference for the Ca5 site in agreement with its small ionic radius. 
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3.4 In vitro Sr release and preliminary results on inflammation reactions in contact with Sr-
HAp 
The release of strontium after interaction in Sr–free culture medium (DMEM) is presented for 
HAp and Sr-HAp samples in Figure 7. The detection level (around 0.04 ppm) is represented 
by the horizontal line. Whereas no significant amount of Sr is released from undoped sample, 
measurable quantity of strontium ions are detected for Sr-HAp sample. The plateau 
concentration of ionic products (0.2 ppm) is reached after only a few days. This is an 
interesting amount for osteoporosis therapy: indeed it is in the same order of magnitude than 
the one measured in vivo in plasmas of animals treated with Sr-based drugs which were found 
to have obvious anti-osteoporotic effects [1]. The easy delivery of Sr2+ ions in biological 
conditions can be related to the observed substitution of Ca for Sr in the whitlockite phase 
present in Sr-doped ceramics; accordingly with the high solubility product of whitlockite 
compare to hydroxyapatite [37]. Indeed, some substituted strontium in the Hydroxyapatite 
phase is still present in the materials after this interaction time and could serve as a reservoir 
for future osteointegration of the implant upon bone re-modelling. Optimization of the 
preparation could allow to finely tune the ceramic composition (HAp/β-TCP) and thus allow a 
fine tuning of the delivery rate on different time scales. 
 
3.4 Inflammatory process study: TNF-α production 
In order to investigate how strontium-substituted HAp sample modulate TNF-α synthesis, 
monocytes cells were incubated with HAp and Sr:HAp powder for 6 hours. After 6 hours, the 
level of TNF-α protein was not detected in control cells. Due to the low production of TNF-α 
induced by the HAp powder, we have stimulated cells with LPS to investigate if the strontium 
had an influence on TNF-α production (Figure 8). The production of TNF-α significantly 
decreases for Sr-doped HAp powder (values normalized to LPS stimulated cells).Thus 
strontium has a positive effect on cytokines production possibly decreasing the inflammatory 
reactions of human monocytes in contact with HAp powder. Further work is under way to 
study the effect of Sr concentration and the production of other inflammatory and anti-
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inflammatory cytokines. Nevertheless, this is a first promising result allowing the use of Sr-
doped HAp to limit the inflammatory process during HAp implantation [50, 51].  
 
 
4. Conclusions 
The sol-gel process has been successfully used to prepare Sr-doped calcium phosphates. All 
samples are porous and exhibit phase mixtures. With respect to undoped sample, the Sr-doped 
sample exhibits higher proportion of β-TCP phase and significant amount of amorphous 
phase. As far as the substitution is concerned, Sr2+ ions are found in three phases, HAp, β-
TCP and an amorphous phase defined as (Ca,Sr)O. These strontium ions are preferentially 
found in the crystalline phases (60 %) both in HAp (32%) and b-TCP (28%) but a large 
amount (40%) are found in the amorphous phase. From these results, it is clear that doping 
can be efficiently used to modulate the phase proportions and thus the solution behaviour of 
the material. The effective partial substitution of Sr in HAp makes this material very 
interesting for orthopaedic applications. The Sr-HAp cell parameters agree fairly well with the 
Vegard’s law and Sr2+ ions substitute for Ca2+ only in the Ca2 site at low level of substitution. 
Sr substitution in whitlockite occurs preferentially in the Ca4 site which presents an unusually 
low 3-fold coordination in the pure Ca3(PO4)2 phase.  
Furthermore, the presence of Sr-containing amorphous phase and Sr-doped soluble β-TCP 
phase, are responsible for a partial release of Sr2+ ions in solution upon interaction in 
physiological fluids. The level of Sr2+ release in solution is very promising in the view of a 
possible anti-osteoporotic effect demonstrated by other commercial drugs. For the first time to 
our knowledge, a significant anti-inflammatory effect of Sr-doped HAp has been 
demonstrated by measuring the production of TNF-α by human monocytes in contact with the 
materials. Considering all these results, these materials appear to be good candidate for bone 
substitutes or bone tissue engineering applications combining, good bioactivity, expected anti-
osteoporotic properties because of the presence of strontium and anti-inflammatory properties.    
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Table 1 : Nominal and experimental concentrations (weight %) of Ca, P, Sr in HAp and Sr 
HAp samples. determined by ICP-AES 
 HAp Sr HAp 
Ca Nominal 39.88 37.02 
Ca Experimental 38.46 38.79 
P Nominal 18.50 18.07 
P Experimental 17.21 18.42 
Sr Nominal - 4.26 
Sr Experimental - 4.23 
% substitution theoretical - 5 
% substitution experimental - 5 
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Table 2: Refinement results on the hydroxyapatite phase in the two HAp and Sr:HAp 
samples. 
Phase Atom Site x y z Biso (Å2) Occ.b 
        
Ca5(PO4)3(OH) 
P63/m, Z = 2 
a = 9.4239(1) Å 
c = 6.8841(1) Å 
RBragg a = 0.026; 0.013 
Rp a = 0.021; 0.018 
Rwp a = 0.029; 0.027 
Ca1 
Ca2 
P1 
O1 
O2 
O3 
O4 
H4 
4f 
6h 
6h 
6h 
6h 
12i 
4e 
4e 
1/3 
0.2462(1) 
0.3988(2) 
0.3260(3) 
0.5875(3) 
0.3407(2) 
0 
0 
2/3 
0.9926(1) 
0.3691(2) 
0.4830(3) 
0.4653(3) 
0.2559(2) 
0 
0 
0.0013(2) 
¼ 
¼ 
¼ 
¼ 
0.0704(2) 
0.2030(9) 
0.073(3) 
0.29(2) 
= B(Ca1) 
0.38(3) 
0.12(3) 
= B(O1) 
= B(O1) 
= B(O1) 
= 1.2xB(O1) 
1(-) 
1(-) 
1(-) 
1(-) 
1(-) 
1(-) 
½(-) 
½(-) 
        
Ca4.88(1)Sr0.12(1)(PO4)3(OH) 
P63/m, Z = 2 
a = 9.4305(3) Å 
c = 6.8887(2) Å 
RBragg a = 0.028; 0.017 
Rp a = 0.012; 0.018 
Rwp a = 0.016; 0.026 
Ca1 
Ca2 
Sr2 
P1 
O1 
O2 
O3 
O4 
H4 
4f 
6h 
6h 
6h 
6h 
6h 
12i 
4e 
4e 
1/3 
0.2469(2) 
= x(Ca2) 
0.4016(4) 
0.3289(7) 
0.5849(7) 
0.3416(4) 
0 
0 
2/3 
0.9932(3) 
= y(Ca2) 
0.3694(4) 
0.4829(7) 
0.4627(7) 
0.2563(5) 
0 
0 
0.0036(6) 
¼ 
= z(Ca2) 
¼ 
¼ 
¼ 
0.0704(5) 
0.191(1) 
0.057(3) 
0.43(4) 
= B(Ca1) 
= B(Ca1) 
0.27(7) 
0.54(8) 
= B(O1) 
= B(O1) 
= B(O1) 
= 1.2xB(O1) 
1(-) 
0.964(2) 
= 1-Occ(Ca2)
1(-) 
1(-) 
1(-) 
1(-) 
½(-) 
½(-) 
a two values represent the measurements performed at 150 and 350 mm respectively, b site 
occupancy factor. 
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Table 3: Refinement results on the withlockite phase in the Sr:HAp sample. 
Phase Atom Site x y z Biso (Å2) Occ.b 
        
Ca2.87(6)Sr0.13(6)(PO4)2 
R3c, Z = 21 
a = 10.4471(4) Å 
c = 37.391(2) Å 
RBragg a = 0.041; 0.027 
Rp a = 0.012; 0.018 
Rwp a = 0.016; 0.026 
Ca1 
Ca2 
Ca3 
Sr3 
Ca4 
Sr4 
Ca5 
Sr5 
P1 
P2 
P3 
O1 
O2 
O3 
O4 
O5 
O6 
O7 
O8 
O9 
O10 
18b 
18b 
18b 
18b 
6a 
6a 
6a 
6a 
6a 
18b 
18b 
18b 
18b 
18b 
18b 
18b 
18b 
18b 
18b 
18b 
6a 
0.728(1) 
0.620(1) 
0.7320(9) 
= x(Ca3) 
0 
= x(Ca4) 
0 
= x(Ca5) 
0 
0.683(1) 
0.651(2) 
0.714(3) 
0.758(4) 
0.743(5) 
0.507(3) 
0.603(4) 
0.567(3) 
0.117(3) 
0.630(3) 
0.024(3) 
0 
0.861(2) 
0.816(2) 
0.843(1) 
= y(Ca3) 
0 
= y(Ca4) 
0 
= y(Ca5) 
0 
0.862(3) 
0.848(2) 
-0.105(4) 
0.766(4) 
0.006(4) 
0.756(5) 
-0.043(4) 
0.697(5) 
0.919(4) 
0.835(3) 
0.871(3) 
0 
0.1700(7) 
-0.0311(7)
0.0634(7) 
= z(Ca3) 
-0.0822(8)
= z(Ca4) 
0.7329(8) 
= z(Ca5) 
0(-) 
0.8656(8) 
0.7651(7) 
-0.088(1) 
0.851(1) 
0.850(1) 
0.861(1) 
0.775(1) 
0.783(1) 
0.777(1) 
0.729(1) 
-0.019(1) 
0.045(1) 
0.30(9) 
= B(Ca1) 
= B(Ca1) 
= B(Ca1) 
= B(Ca1) 
= B(Ca1) 
= B(Ca1) 
= B(Ca1) 
1.8(2) 
= B(P1) 
= B(P1) 
1.0(1) 
= B(O1) 
= B(O1) 
= B(O1) 
= B(O1) 
= B(O1) 
= B(O1) 
= B(O1) 
= B(O1) 
= B(O1) 
1(-) 
1(-) 
0.90(2) 
= 1-Occ(Ca3)
0.25(2) 
= ½-Occ(Ca4)
0.96(2) 
= 1-Occ(Ca5)
1(-) 
1(-) 
1(-) 
1(-) 
1(-) 
1(-) 
1(-) 
1(-) 
1(-) 
1(-) 
1(-) 
1(-) 
1(-) 
a two values represent the measurements performed at 150 and 350 mm respectively, b site 
occupancy factor. 
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Table 4: Results of the quantitative phase analyses using the Rietveld method. An amorphous 
(Ca,Sr)O amount was estimated assuming the refined values for the crystalline phases and the 
synthesis conditions: (Ca+Sr)/PO4= 1.67 with 5 at % of Sr. 
Sample  Apatite Sr:apatite 
(Ca+Sr)/PO4 1.67 1.67 Synthesis 
Sr amount 0 % 5.0 % 
Phase Formula Wt % Formula Wt % 
Apatite Ca5(PO4)3(OH) 92.8(6) Ca4.88(1)Sr0.12(1)(PO4)3(OH) 66.5(6) 
whitlockite Ca3(PO4)2 7.0(3) Ca2.87(6)Sr0.13(6)(PO4)2 32.6(5) 
lime CaO 0.2(1) CaO 0.5(1) 
portlandite - - Ca(OH)2 0.4(1) 
(Ca+Sr)/PO4 1.66(2) 1.63(3) 
Refined 
Sr amount 0(-) % 2.86(4) % 
Phase   Formula Wt % 
apatite   Ca4.88Sr0.12(PO4)3(OH) 65.0 
whitlockite   Ca2.87Sr0.13(PO4)2 31.9 
lime   CaO 0.5 
portlandite   Ca(OH)2 0.4 
amorphousa   (Ca,Sr)Oamorph. 2.2 
(Ca+Sr)/PO4  1.67(-) 
Estimated 
assuming 
the used 
synthesis 
ratios 
Sr amount  5.0(-) % 
a refers to ‘an amorphous (Ca,Sr)O’ in the text. 
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Figure 1: Representative SEM image of sol-gel derived HAp samples. 
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Figure 2: Powder patterns from the Joint Rietveld on the HAp sample. Two sample-to-
detector distances represent top (150 mm) and bottom (350 mm) plots. The data were 
measured at SNBL, ESRF with MAR345 Image Plate detector and λ = 0.710130 Å. Observed 
(a1 and a2; red dots), calculated (a1 and a2; black lines) and difference (b1 and b2; blue lines) 
powder diffraction patterns are presented. Bragg positions are indicated by green vertical bars 
for hydroxyapatite (c1 and c2), whitlockite (d1 and d2) and lime (e1 and e2). 
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Figure 3: Powder patterns from the joint Rietveld on the Sr:HAp sample. Two sample-to-
detector distances represent top (150 mm) and bottom (350 mm) plots. The data were 
collected at SNBL, ESRF with MAR345 Image Plate detector and  λ = 0.710130 Å. Observed 
(a1 and a2; red dots), calculated (a1 and a2; black lines) and difference (b1 and b2; blue lines) 
powder diffraction patterns are presented. Bragg positions are indicated by green vertical bars 
for hydroxyapatite (c1 and c2), whitlockite (d1 and d2), lime (e1 and e2) and portlandite (f1 
and f2). 
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Figure 4: Lattice parameters (top) and unit cell volume (bottom) as a function of the x value 
for the solid solution Ca10-xSrx(PO4)6(OH)2. Details on the Ca-rich side are shown in the 
insets. 
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Figure 5: Calcium environments of Ca1 site (a) and Ca2 site (b) in the hydroxyapatite 
structure. Grey, pink, red and blue balls represent respectively calcium, phosphorus and 
oxygen atoms and hydroxyl groups. Phosphate tetrahedra are coloured in pink. 
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Figure 6: Calcium environments of Ca1 site (a), Ca2 site (b), Ca3 site (c), Ca4 site (d) and 
Ca5 site (e) in the whitlockite structure. Grey, pink and red balls represent respectively 
calcium, phosphorus and oxygen atoms. Phosphate tetrahedra are coloured in pink. 
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Figure 7 : Release of strontium ions as a function of interaction time for Sr-HAp (solid line) 
and HAp (dotted line) samples. The horizontal grey line represents the detection level. 
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Figure 8 : Tumor Necrosis Factor (TNF-α) production by human monocytes cultured for 6 
hours with LipoPolySaccharide (LPS) without material and in contact with HAp and Sr-HAp 
samples (* means p<0.05). 
 
 
